New Pharmacological Insights into Aprotinin: Expanding Perioperative Hemostatic Drug Options

A landmark in vitro coagulation study published in TH Open has clarified the full action pathway of aprotinin, a classic hemostatic agent once withdrawn over safety concerns. The findings update industry understanding and bring new medication strategies for cardiac surgery, liver transplantation and ECMO treatment.

Researchers conducted comprehensive head-to-head in vitro comparisons between aprotinin and widely used tranexamic acid (TXA). While both potently suppress fibrinolysis to cut intraoperative blood loss, their mechanisms differ drastically. TXA only exerts antifibrinolytic effects, whereas aprotinin delivers dual pharmacological benefits. At clinical therapeutic concentrations, aprotinin specifically blocks kallikrein and factor XIa to curb overactivation of the intrinsic coagulation cascade. It does not directly neutralize thrombin and barely interferes with physiological extrinsic clotting.

Platelet assays yielded fresh results: aprotinin does not hinder normal platelet aggregation triggered by thrombin or collagen. It merely blocks plasmin-induced platelet damage and preserves platelet function during operations.

Industry experts note aprotinin’s rare advantage of suppressing pathological coagulation without disrupting natural hemostasis, translating to lower bleeding risks than existing agents. Beyond conventional cardiac procedures, its mechanism supports expanded use in extracorporeal circulation therapies such as ECMO, offering a differentiated research direction for novel perioperative hemostatic drugs.

FOR DETAIL: https://doi.org/10.1055/s-0041-1735154

Article from: